HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s SCCS Reissues Guidance On Cosmetic Ingredient Testing With Updated Non-Animal Method Perspectives

This article was originally published in The Rose Sheet

Executive Summary

The Scientific Committee on Consumer Safety’s guidance offers perspective on new approach methodologies that can be used to substantiate cosmetic ingredient safety, as well as areas where alternative strategies continue to be insufficient. The document also includes updated criteria for multi-constituent natural ingredients at a time of increasing industry use.

You may also be interested in...



Cosmetic Brands, And Animals, Have Growing Problem In Europe; Commission’s Nanomaterials Report

The European Commission’s Scientific Committee for Consumer Safety has been unable to get the data it needs to properly assess the safety of nanomaterials in cosmetic products. The European Commission expects REACH to address the issue, and that is probably not a prospect that industry stakeholders relish.

ICCR’s Growing Membership Ensures Diverse Cosmetics Regulatory Perspectives – PCPC

South Korea’s Ministry of Food and Drug Safety and Taiwan’s Food and Drug Administration will transition from ICCR observers to full members, joining regulatory authorities from the US, Europe, Japan, Canada and Brazil. PCPC’s Francine Lamoriello, EVP of global affairs, discusses.

Are Cosmetic Endocrine-Disruptor Checks Sufficient? EU Commission Issues Long-Awaited Position

Industry no doubt welcomes the Commission’s long-overdue review of the European Cosmetics Regulation as it pertains to chemicals with endocrine-disrupting properties. The report concludes that the existing regulatory framework is adequate to evaluate and manage suspected endocrine disruptors, while putting stakeholders on notice that a number of prioritized ingredients will be up for review in 2019.   

Related Content

Topics

UsernamePublicRestriction

Register

RS122496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel